Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

CDRE vs COCH: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CDRE Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 8–2 Matrix Metrics)

CDRE Overall Winner 6-Pillar Tally: CDRE 6 – 0 COCH Matrix Metrics: CDRE 8 – 2 COCH

As of Nov 20, 2026, Cadre Holdings, Inc. (CDRE) is the stronger overall head-to-head candidate over Envoy Medical, Inc. (COCH) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CDRE carries a Unified Composite Score of 39.6/100 (SELL) at $29.45 (18.5x Forward P/E, 12.5% operating margin), whereas COCH carries 35.1/100 (SELL) at $6.70 (N/M Forward P/E, -10261.0% operating margin).

  • Growth vs. Quality Trade-Off: CDRE earns the overall head-to-head edge with a stronger Unified Composite Score (39.6/100 SELL vs. COCH 35.1/100 SELL) and 0.87β · 42% Vol risk profile, whereas COCH leads top-line expansion (+57.1% YoY revenue growth, N/M PEG, and 0 of 6 institutional pillars) for higher-beta growth mandates.
  • Defensive Composite Rating Caution: Although CDRE compares more favorably head-to-head, both CDRE (39.6/100 SELL) and COCH (35.1/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CDRE vs COCH
CDRE NYSE Head-to-Head Winner
Cadre Holdings, Inc.
Orthopedic, Prosthetic & Surgical Appliances & Supplies
$29.45
-3.63% 1D
Market Cap $1.3B
TTM Revenue $733M
Forward P/E 18.5x
Beta / 30D Vol 0.87β · 42% Vol
Unified Composite Score
39.6 / 100 SELL
Tech 15.0 Fund 40.0 Flow 55.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 43
RSI-14: 42.7 · SMA20: $31.80 · SMA50: $28.53
COCH NASDAQ
Envoy Medical, Inc. Class A Common Stock
Orthopedic, Prosthetic & Surgical Appliances & Supplies
$6.70
+0.0% 1D
Market Cap $51.9M
TTM Revenue $231,000
Forward P/E N/M
Beta / 30D Vol 4.94β · 3352% Vol
Unified Composite Score
35.1 / 100 SELL
Tech 50.0 Fund 27.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (348.7% over 20 days), RSI 78
RSI-14: 77.7 · SMA20: $6.79 · SMA50: $3.12

6-Pillar Scorecard Institutional Category Breakdown (CDRE 6 – 0 COCH)

Columns: Metric · CDRE · COCH
1. Valuation Multiples CDRE
Forward P/E 18.5x N/M
Trailing P/E 33.6x N/M
PEG Ratio N/M N/M
EV / Revenue 2.2x 119.2x
2. Growth & Scale CDRE
Revenue Growth (YoY) +30.2% +57.1%
Earnings Growth (YoY) +37.5% +0.0%
TTM Revenue (USD) $733M $231,000
Market Cap $1.3B $51.9M
3. Profitability & Quality CDRE
Gross Margin 42.8% N/A
Operating Margin 12.5% -10261.0%
Net Profit Margin 5.6% 0.0%
Return on Equity (ROE) 11.6% 0.0%
4. Balance Sheet & Cash Flow CDRE
Cash Generation (TTM) $76M -$21M
Cash Flow Margin 10.4% N/A
Net Cash / Leverage $330M Net Debt (1.08x D/E) $24M Net Cash
Dividend Yield 1.24% None (0.00%)
5. Options & Positioning CDRE
Options Structure Phase SURGE UNCLASSIFIED
Current IV / %ile 47.3% (2nd %ile) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase DISTRIBUTION · Neutral NEUTRAL · Markup
6. R&D & Supply-Chain Moat CDRE
OpEx & R&D Intensity 30.3% of Rev ($222M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Aerospace & Defense Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CDRE (8) vs COCH (2)
Institutional Metric CDRE COCH Criterion Row Edge
Market Capitalization
Scale
$1.3B $51.9M Larger Scale CDRE
Trailing P/E Ratio
Valuation
33.6x N/M Lower Multiple CDRE
Forward P/E Ratio
Valuation
18.5x N/M Lower Multiple CDRE
Revenue Growth (YoY)
Growth
+30.2% +57.1% Higher Growth COCH
Operating Margin (TTM)
Profitability
12.5% -10261.0% Higher Margin CDRE
Net Profit Margin
Profitability
5.6% 0.0% Higher Margin CDRE
Return on Equity (ROE)
Capital Efficiency
11.6% 0.0% Higher ROE CDRE
52-Week Range Position
Momentum
22% ($24–$49) 89% ($0–$7) Stronger Trend COCH
Beta / 30D Volatility
Risk Regime
0.87β · 42% Vol 4.94β · 3352% Vol Lower Realized Risk CDRE
Unified Institutional Score
Composite Signal
39.6 / 100 (SELL) 35.1 / 100 (SELL) Higher Composite CDRE
Trailing 12M Revenue (USD)
Operating Scale
$733M $231,000 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
42.8% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 2.2x EV/Rev N/M PEG · 119.2x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$76M ($330M Net Debt (1.08x D/E)) -$21M ($24M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon COCH +1024.38 pp
CDRE: -0.03% · COCH: +1024.35%
3M Horizon COCH +808.85 pp
CDRE: -10.97% · COCH: +797.88%
6M Horizon COCH +847.83 pp
CDRE: -2.84% · COCH: +844.99%
1Y Horizon COCH +869.78 pp
CDRE: -26.38% · COCH: +843.4%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period CDRE Revenue COCH Revenue CDRE Op. Margin COCH Op. Margin Margin Leader
FY2020 $400M N/A 12.3% N/A CDRE
FY2021 $430M N/A 12.1% N/A CDRE
FY2022 $460M $0M 3.7% -3673.4% CDRE
FY2023 $480M $0M 11.7% -5809.8% CDRE
FY2024 $570M $0M 11.8% -8558.2% CDRE
FY2025 $610M $0M 11.0% -9240.7% CDRE

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CDRE SURGE
9d in phase · OBV DISTRIBUTION
Current IV 47.3%
IV Percentile 2nd %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow DISTRIBUTION
Exact CDRE Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
COCH UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact COCH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CDRE Moat Profile Cyclical / Execution-Driven Positioning
Aerospace & Defense Operator
Competes within the Aerospace & Defense value chain with $1.3B market capitalization and 12.5% operating margin.
OpEx & R&D Reinvestment 30.3% of Rev ($222M)
90D Engineering Disclosures 0 Published
COCH Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $51.9M market capitalization and -10261.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ CDRE vs COCH Key Questions & Quantitative Answers

As of Nov 20, 2026, Cadre Holdings, Inc. (CDRE) is the stronger overall head-to-head candidate over Envoy Medical, Inc. (COCH) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CDRE carries a Unified Composite Score of 39.6/100 (SELL) at $29.45 (18.5x Forward P/E, 12.5% operating margin), whereas COCH carries 35.1/100 (SELL) at $6.70 (N/M Forward P/E, -10261.0% operating margin). Growth vs. Quality Trade-Off: CDRE earns the overall head-to-head edge with a stronger Unified Composite Score (39.6/100 SELL vs. COCH 35.1/100 SELL) and 0.87β · 42% Vol risk profile, whereas COCH leads top-line expansion (+57.1% YoY revenue growth, N/M PEG, and 0 of 6 institutional pillars) for higher-beta growth mandates. Defensive Composite Rating Caution: Although CDRE compares more favorably head-to-head, both CDRE (39.6/100 SELL) and COCH (35.1/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

CDRE leads the Growth & Scale pillar: CDRE posts +30.2% YoY revenue growth and +37.5% YoY earnings growth on $733M TTM revenue (42.8% gross margin, 12.5% operating margin), compared with COCH at +57.1% YoY revenue growth and +0.0% YoY earnings growth on $231,000 TTM revenue (N/A gross margin, -10261.0% operating margin). Across the 6-period historical trajectory (FY2020 to FY2025), CDRE cumulative revenue shifted +52.5% while COCH shifted N/A. In operating R&D and SG&A reinvestment, CDRE deploys 30.3% of Rev ($222M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for COCH.

CDRE screens cheaper on headline valuation multiples. CDRE trades at 18.5x Forward P/E, 33.6x Trailing P/E, N/M PEG, and 2.2x EV/Revenue (10.4% FCF margin), whereas COCH trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 119.2x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CDRE (11.6% ROE) versus COCH (0.0% ROE) capital efficiency.

In options market volatility and institutional positioning, CDRE carries 47.3% implied volatility (2nd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a SURGE options structure phase (0.87β · 42% Vol realized risk). By comparison, COCH carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (4.94β · 3352% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.